Long-acting siRNA therapies for hypertension offer a vaccine-like paradigm shift that removes the daily burden of adherence but may introduce behavioral risks such as pharmacological moral hazard.
Long-acting siRNA therapies for hypertension could solve daily adherence issues but require health systems to redesign care to maintain patient engagement in lifestyle modifications.
Abstract: Global hypertension control remains stagnant due to the fragility of daily medication adherence rather than a lack of effective drugs. Long-acting siRNA therapies offer a “vaccine-like” paradigm shift, transferring responsibility from the patient’s daily memory to the health system’s reliability. This approach introduces “pharmacological moral hazard,” where patients may neglect lifestyle modifications under a false sense of total security. Realizing the promise of democratized protection requires redesigning care pathways to ensure that infrequent dosing does not lead to clinical disengagement.
Corrêa et al. (2026) conducted a review in Hypertension. Long-acting siRNA therapies (e.g., zilebesiran) was evaluated. Long-acting siRNA therapies for hypertension offer a vaccine-like paradigm shift that removes the daily burden of adherence but may introduce behavioral risks such as pharmacological moral hazard.